Back to home

Clinical effectiveness of Fobumix Easyhaler® for patients with poorly controlled obstructive airway disease: a real-world study of patient-reported outcomes

Insights | 10/03/2020

Prescribing information available here

  • The clinical effectiveness and patient satisfaction of budesonide/formoterol dry powder inhaler Fobumix Easyhaler® was evaluated in patients with asthma, chronic obstructive pulmonary disease (COPD), and asthma, COPD overlap (ACO) in daily clinical practice.
  • The use of Fobumix Easyhaler® significantly improved disease control, quality of life, and lung function in all patient groups when switched from MDI, Turbohaler or Accuhaler to Easyhaler(P≤0.002).
  • Patients were satisfied with the use of Fobumix Easyhaler®, and most patients learned to use it in less than 5 minutes.

Inhalation is the most recommended route for administering medication for asthma and COPD patients. Therefore, inhalation technique and inhaler device are important factors in achieving an effective clinical response. Here, the effectiveness of Fobumix Easyhaler® was assessed in a 12-week real-world, multicenter, open-label, non-randomized, non-interventional study among 1498 patients with asthma, COPD, or ACO in Hungary. The majority of patients were switched to Easyhaler from other inhalers, most commonly from metered dose inhaler (MDI) (24%), Turbohaler®* (19%), or Accuhaler®* (14.5%).

Clinical effectiveness in patients with asthma or ACO (N=720) was evaluated based on disease control (Asthma Control Test, ACT), quality of life (mini-Asthma Quality of Life Questionnaire, mini-AQLQ), and lung function (forced expiratory volume in 1s, FEV1% predicted measurement). Similarly, in the COPD and ACO patient group (N=877), disease control was evaluated by COPD assessment test (CAT), quality of life based on the modified Medical Research Council (mMRC) dyspnea scale, and lung function by FEV1% predicted measurements. Satisfaction among patients who switched from other inhalers (N=1043) was recorded by a questionnaire in a scale from 1 (very good) to 6 (unsatisfying).

The results showed that the use of Fobumix Easyhaler significantly improved disease control as demonstrated by the changes in the ACT score (from 14.2 to 21.0, P<0.001) and CAT score (from 24.2 to 18.2, P<0.001) when switched from MDI, Turbohaler or Accuhaler to Easyhaler (Figure 1). Treatment with Fobumix Easyhaler also improved the quality of life in all patient groups (P<0.001). In addition, the use of Fobumix Easyhaler resulted in significant improvement in lung function across all patient groups (P<0.001), and importantly, also in patients who were switched from previous inhalers (P<0.001).

After 12 weeks of treatment with Fobumix Easyhaler, the majority (87.2%) of asthma patients were able to reduce the use of a reliever inhaler. More than 90% of physicians considered Fobumix Easyhaler as very easy or easy to teach and use, and most patients (73.8%) learned the technique in less than 5 minutes. Notably, 72.4% of the patients rated Fobumix Easyhaler as “very good”, whereas corresponding results for MDI, Turbohaler*, and Accuhaler* were 12.7%, 17.3%, and 18%, respectively.


Orion_wehale_insights_Tamasi_Figure 1_ME_20180912.png

Figure 1. Fobumix Easyhaler therapy improves disease control among patients with asthma, COPD, and ACO. N(total)=1498 patients (621 with asthma, 778 with COPD, and 99 with ACO; 455 newly diagnosed patients and 1043 patients switching from another inhaler device). *P<0.001 for average ACT and CAT score,**Impact of COPD symptoms on everyday life. Patients received 12 weeks of budesonide/formoterol Fobumix Easyhaler therapy. 

This real-life study showed that Fobumix Easyhaler significantly improved disease control, quality of life and lung function among patients with asthma, COPD, and ACO when patients were switched from MDI, Turbohaler and Accuhaler. The inhaler was considered easy to teach and use, and the majority of patients rated the user satisfaction of Fobumix Easyhaler with the highest grade on the scale used.

*This article refers to UK brand names. Within the clinical papers the brand names reflect the location of
where the studies took place.

Date of preparation: February 2020 / RESP-330bdb


Tamási L, Szilasi M, Gálffy G. Clinical Effectiveness of Budesonide/Formoterol Fumarate Easyhaler® for Patients with Poorly Controlled Obstructive Airway Disease: a Real-World Study of Patient-Reported Outcomes. Adv Ther.
2018 Aug;35(8):1140-1152.


Orion is a globally operating Finnish pharmaceutical company - a builder of well-being for more than 100 years. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. Respiratory diseases are one of Orion’s core therapy areas. Orion's net sales in 2018 amounted to EUR 977 million and the company had about 3,200 employees. Orion's A and B shares are listed on Nasdaq Helsinki.® ®

As a forward-looking pharmaceutical company, Orion continues to invest in research and development of treatment options for people with asthma and COPD. The focus is on safety and quality in each step of the product life cycle while taking care of the environment. Sustainability is entwined in the whole process from R&D through manufacturing. It is also required of Orion’s providers. Orion is committed to keeping the best possible control of the environmental impacts of their own factories by reducing energy consumption and the impact of their waste waters, among others, and is making good progress in that regard. Orion works to ensure that suppliers have procedures in place to control and reduce their own environmental impacts as well. All aspects of sustainability - social, economic and environmental - are carefully considered in the whole product life cycle, including patient use and the disposal of old inhalers.


You may download the Orion Sustainability Report 2018 here


Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300.



Full prescribing information available here


MAY 2021 / RESP-330b(3)


Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Orion Pharma (UK) Ltd on 01635 520300.

Orion Pharma (UK) Ltd, Abbey Gardens, 4 Abbey Street, Reading, RG1 3BA, UK | Tel: +44 1635 520 300 | February 2021 / RESP-330(1)
Policies Contact us Orion Corporation 2021